World's Best Scientists 2026 revealed!
Ronald Herbst

Ronald Herbst

D-Index & Metrics

Immunology

D-Index
51
Citations
11698
World Ranking
4130
National Ranking
31

Ronald Herbst publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Ronald Herbst sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 165 publications — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Ronald Herbst D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Ronald Herbst sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 51 D-Index — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Ronald Herbst is affiliated with Biolojic Design in Israel. Their research primarily focuses on medicine, with significant contributions to the fields of immunology and microbiology. Within these areas, Herbst has explored subfields such as immunology, oncology, infectious diseases, molecular biology, and neurology.

Their work addresses several main topics, including:

  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • CAR-T Cell Therapy Research
  • Tuberculosis Research and Epidemiology
  • Atherosclerosis and Cardiovascular Diseases
  • T-cell and B-cell Immunology
  • Cytokine Signaling Pathways and Interactions

Herbst has published articles in a number of scientific journals, with frequent appearances in:

  • Clinical Cancer Research
  • Cancer Discovery
  • Molecular Cancer Therapeutics
  • Communications Biology
  • Cancer Immunology Research

Notable recent papers authored or co-authored by Herbst include:

  • Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment, 2020, Clinical Cancer Research
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown, 2021, Cancer Discovery
  • Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR, 2021, Molecular Cancer Therapeutics
  • Immunofibroblasts regulate LTα3 expression in tertiary lymphoid structures in a pathway dependent on ICOS/ICOSL interaction, 2022, Communications Biology
  • Immunomodulation of T- and NK-cell Responses by a Bispecific Antibody Targeting CD28 Homolog and PD-L1, 2021, Cancer Immunology Research

Throughout their career, Herbst has collaborated frequently with several researchers, including:

  • Kathy Mulgrew
  • Philip Martin
  • Andrew Garcia
  • Gianluca Carlesso
  • Susannah L. Hewitt

Best Publications

  • HMGB1 and RAGE in inflammation and cancer.

    Gary P. Sims;Daniel C. Rowe;Svend T. Rietdijk;Ronald Herbst

  • Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

    Pascale André;Caroline Denis;Caroline Soulas;Clarisse Bourbon-Caillet

  • Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

    Heng Lin;Shuang Wei;Elaine M. Hurt;Michael D. Green

  • The Immunoscore: Colon Cancer and Beyond

    Helen K. Angell;Daniela Bruni;J. Carl Barrett;Ronald Herbst

  • TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

    Jerome Biton;Jerome Biton;Audrey Mansuet-Lupo;Nicolas Pécuchet;Marco Alifano

  • Targeting CD73 in the tumor microenvironment with MEDI9447

    Carl M. Hay;Erin Sult;Qihui Huang;Kathy Mulgrew

  • Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.

    Liyan Jiang;Jiaqi Huang;Brandon W. Higgs;Zhibin Hu

  • Kinesin motor proteins as targets for cancer therapy

    Dennis Huszar;Maria-Elena Theoclitou;Jeffrey Skolnik;Ronald Herbst

  • Retraction Note: Microglia-dependent synapse loss in type I interferon-mediated lupus.

    Allison R. Bialas;Jessy Presumey;Abhishek Das;Cees E. van der Poel

  • Cell Distance Mapping Identifies Functional T Follicular Helper Cells in Inflamed Human Renal Tissue

    Vladimir M. Liarski;Natalya Kaverina;Anthony Chang;Daniel Brandt

  • Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

    Unknown

  • B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase.

    Sarah L. Pogue;Tomohiro Kurosaki;Joseph Bolen;Ronald Herbst

  • Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

    Stefanie R. Mullins;John P. Vasilakos;Katharina Deschler;Iwen Grigsby

  • Self-reactive IgE exacerbates interferon responses associated with autoimmunity

    Jill Henault;Jeffrey M Riggs;Jodi L Karnell;Vladimir M Liarski

  • B cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody

    Ronald Herbst;Yue Wang;Sandra Gallagher;Nanette Mittereder

  • MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis

    Wen Pan;Shu Zhu;Dai Dai;Zheng Liu

  • CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.

    Ralph F. Alderson;Robert J. Kreitman;Tianling Chen;Peter Yeung

  • The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

    Diane Damotte;Sarah Warren;Jennifer Arrondeau;Pascaline Boudou-Rouquette

  • IL-22 Increases Permeability of Intestinal Epithelial Tight Junctions by Enhancing Claudin-2 Expression

    Yaya Wang;John Brian Mumm;Ronald Herbst;Roland Kolbeck

  • S100A9 Induced Inflammatory Responses Are Mediated by Distinct Damage Associated Molecular Patterns (DAMP) Receptors In Vitro and In Vivo

    Bo Chen;Allison L. Miller;Marlon Rebelatto;Yambasu Brewah

  • B-cell targeted therapeutics in clinical development

    Stephan Blüml;Kathleen McKeever;Rachel Ettinger;Josef Smolen

  • Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

    Melissa Damschroder;Peter Kiener;Herren Wu;William Dall'acqua

Frequent Co-Authors

Herren Wu
Herren Wu AstraZeneca (United Kingdom)
Peter A. Kiener
Peter A. Kiener AstraZeneca (United Kingdom)
Anthony J. Coyle
Anthony J. Coyle Takeda (United States)
Roland Kolbeck
Roland Kolbeck AstraZeneca (United Kingdom)
Isabelle Cremer
Isabelle Cremer Sorbonne University
Michael C. Carroll
Michael C. Carroll Boston Children's Hospital
Thomas F. Tedder
Thomas F. Tedder Duke University
Guy Brusselle
Guy Brusselle Ghent University Hospital
Bart N. Lambrecht
Bart N. Lambrecht Ghent University
Ken R. Bracke
Ken R. Bracke Ghent University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring complementary healthcare degrees can open diverse career opportunities. Many students transition into nursing roles to gain practical experience with patient care and clinical applications of immunological principles.

For example, accelerated pathways such as accelerated fnp programs offer a fast-track to becoming a Family Nurse Practitioner, integrating immunology knowledge in diagnosing and treating patients.

Individuals without prior nursing education may consider online rn programs for non nurses, which provide flexible and accessible options to begin nursing careers while enhancing their science foundation.

For those entering nursing through a bachelor’s degree, selecting the easiest absn program to get into can reduce admission barriers and shorten the pathway to clinical practice.

Additionally, becoming a Licensed Practical Nurse through programs with lpn programs with easiest admission requirements can be a practical stepping stone, offering hands-on experience related to immune system care in various healthcare settings.

Best Scientists Citing Ronald Herbst

Trending Scientists

Recently Published Articles